Qiagen

Qiagen is a global leader in molecular diagnostics and life sciences, providing over 500,000 customers worldwide with innovative “Sample to Insight” solutions that enable the extraction and analysis of DNA, RNA, and proteins. Founded in 1984 in Germany, QIAGEN now operates in more than 25 countries, with corporate headquarters in the Netherlands and major regional hubs in the U.S., China, and Singapore. Its portfolio includes more than 500 products, such as nucleic acid extraction kits, PCR and digital PCR systems, next-generation sequencing technologies, and advanced bioinformatics tools. These solutions support diverse applications in healthcare, pharmaceuticals, forensics, food safety, and academic research. Notable products include the QuantiFERON-TB test, QIAcuity digital PCR, and QIAstat-Dx for syndromic testing. Publicly traded on the NYSE and Frankfurt Stock Exchange, QIAGEN employs around 6,000 people and reported $1.97 billion in revenue in 2023, with strategic goals focused on growth, innovation, and expanding AI-enabled solutions.